The Kiniksa pipeline has the potential to treat a spectrum of autoinflammatory & autoimmune diseases.
|Program & Target||Indication||Preclin||Phase 1||Phase 2||Phase 3||Mkt||Rights|
|RilonaceptIL-1α & IL-1β||Recurrent Pericarditis||Phase 2||Worldwide (excl. Middle East and North Africa)|
|MavrilimumabGM-CSFRα||Giant Cell Arteritis||Phase 2-ready||Worldwide|
|KPL-716OSMRβ||Prurigo Nodularis / Atopic Dermatitis||Phase 1||Worldwide|
|KPL-045CD30L||T-cell dependent, B-cell-mediated indications||Preclinical||Worldwide|
|KPL-404CD40||T-cell dependent, B-cell-mediated indications||Preclinical||Worldwide|
Rilonacept is an approved, subcutaneously-administered, cytokine trap that inhibits the signaling of IL-1α and IL-1β, two soluble cytokines. There are multiple diseases involving these cytokines where rilonacept may provide benefit, the first of which is in a rare, inflammatory, cardiovascular disease where there are currently no approved therapies. We are planning to initiate a Phase 3 trial of rilonacept in recurrent pericarditis in 2018.
Monoclonal antibody inhibitor of GM-CSF signaling. Studied by MedImmune in over 550 patients in rheumatoid arthritis. Planning a Phase 2 study in Giant Cell Arteritis - an inflammatory disease of blood vessels with unmet need.
Monoclonal antibody inhibitor of both IL-31 and Oncostatin M, cytokines involved in pruritus, Th2 response, fibrosis and barrier dysfunction.
Monoclonal antibody inhibitor of a T-cell co-stimulatory mechanism important in the function of activated T-memory cells.
Monoclonal antibody inhibitor of a central control node of T-cell-dependent, B-cell-mediated humoral adaptive immunity.